182 related articles for article (PubMed ID: 18608912)
61. The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.
Nakouzi A; Zhang T; Oscarson S; Casadevall A
Vaccine; 2009 Jun; 27(27):3513-8. PubMed ID: 19464529
[TBL] [Abstract][Full Text] [Related]
62. Antifungal activity of a human antiglucuronoxylomannan antibody.
Zhong Z; Pirofski LA
Clin Diagn Lab Immunol; 1998 Jan; 5(1):58-64. PubMed ID: 9455881
[TBL] [Abstract][Full Text] [Related]
63. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection.
Mukherjee J; Pirofski LA; Scharff MD; Casadevall A
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3636-40. PubMed ID: 8475112
[TBL] [Abstract][Full Text] [Related]
64. [Disseminated cryptococcosis in patients with AIDS. Clinical, microbiological, and immunological analysis of 51 patients].
Metta HA; Corti ME; Negroni R; Helou S; Arechavala A; Soto I; Villafañe MF; Muzzio E; Castello T; Esquivel P; Trione N
Rev Argent Microbiol; 2002; 34(3):117-23. PubMed ID: 12415893
[TBL] [Abstract][Full Text] [Related]
65. Human defenses against Cryptococcus neoformans: an update.
Brummer E
Mycopathologia; 1998-1999; 143(3):121-5. PubMed ID: 10353206
[TBL] [Abstract][Full Text] [Related]
66. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.
Brandt S; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Sep; 10(5):903-9. PubMed ID: 12965925
[TBL] [Abstract][Full Text] [Related]
67. Enzyme immunoassay detection of IgM to galactoxylomannan of Cryptococcus neoformans.
Reiss E; Cherniak R; Eby R; Kaufman L
Diagn Immunol; 1984; 2(2):109-15. PubMed ID: 6388977
[TBL] [Abstract][Full Text] [Related]
68. Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay.
Belay T; Cherniak R; Kozel TR; Casadevall A
Infect Immun; 1997 Feb; 65(2):718-28. PubMed ID: 9009335
[TBL] [Abstract][Full Text] [Related]
69. Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay.
Belay T; Cherniak R
Infect Immun; 1995 May; 63(5):1810-9. PubMed ID: 7537249
[TBL] [Abstract][Full Text] [Related]
70. Pathogenicity of Cryptococcus neoformans: virulence factors and immunological mechanisms.
Rodrigues ML; Alviano CS; Travassos LR
Microbes Infect; 1999 Apr; 1(4):293-301. PubMed ID: 10602663
[TBL] [Abstract][Full Text] [Related]
71. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.
Nussbaum G; Anandasabapathy S; Mukherjee J; Fan M; Casadevall A; Scharff MD
Infect Immun; 1999 Sep; 67(9):4469-76. PubMed ID: 10456888
[TBL] [Abstract][Full Text] [Related]
72. Polysaccharide antigens of the capsule of Cryptococcus neoformans.
Cherniak R; Sundstrom JB
Infect Immun; 1994 May; 62(5):1507-12. PubMed ID: 8168912
[TBL] [Abstract][Full Text] [Related]
73. Innate host defenses against Cryptococcus neoformans.
Hole C; Wormley FL
J Microbiol; 2016 Mar; 54(3):202-11. PubMed ID: 26920880
[TBL] [Abstract][Full Text] [Related]
74. Enzyme-linked immunosorbent assay for detection and quantification of Cryptococcus neoformans antigen.
Illnait MT; Vilaseca JC; Fernández CM; Martínez GF
Mem Inst Oswaldo Cruz; 2001 Feb; 96(2):241-5. PubMed ID: 11285504
[TBL] [Abstract][Full Text] [Related]
75. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.
Devi SJ; Schneerson R; Egan W; Ulrich TJ; Bryla D; Robbins JB; Bennett JE
Infect Immun; 1991 Oct; 59(10):3700-7. PubMed ID: 1716613
[TBL] [Abstract][Full Text] [Related]
76. Finite-element model of interaction between fungal polysaccharide and monoclonal antibody in the capsule of Cryptococcus neoformans.
Rakesh V; Schweitzer AD; Zaragoza O; Bryan R; Wong K; Datta A; Casadevall A; Dadachova E
J Phys Chem B; 2008 Jul; 112(29):8514-22. PubMed ID: 18588334
[TBL] [Abstract][Full Text] [Related]
77. Clinical and serologic evaluation of cats with cryptococcosis.
Flatland B; Greene RT; Lappin MR
J Am Vet Med Assoc; 1996 Sep; 209(6):1110-3. PubMed ID: 8800258
[TBL] [Abstract][Full Text] [Related]
78. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils.
Monari C; Retini C; Casadevall A; Netski D; Bistoni F; Kozel TR; Vecchiarelli A
Eur J Immunol; 2003 Apr; 33(4):1041-51. PubMed ID: 12672070
[TBL] [Abstract][Full Text] [Related]
79. Synthetic Glycans Reveal Determinants of Antibody Functional Efficacy against a Fungal Pathogen.
Crawford CJ; Guazzelli L; McConnell SA; McCabe O; d'Errico C; Greengo SD; Wear MP; Jedlicka AE; Casadevall A; Oscarson S
ACS Infect Dis; 2024 Feb; 10(2):475-488. PubMed ID: 37856427
[TBL] [Abstract][Full Text] [Related]
80. Polysaccharide diversity in VNI isolates of Cryptococcus neoformans from Roraima, Northern Brazil.
Dal Pupo HD; Sena BAG; Reis FCG; Machado L; Fortes ST; de Almeida Junior JN; Godinho RMC; Rodrigues ML
Fungal Biol; 2019 Oct; 123(10):699-708. PubMed ID: 31542188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
